No Data
No Data
Express News | National Medical Products Administration: Deploys pilot work on segmented production reform of biological products.
Hong Kong stock market anomaly | Genting New Star-B (01952) rose by over 8% again. The company expects three products to achieve commercial listing by the end of the year.
Yunding Xinyao-B (01952) rose by more than 8%, as of the time of publication, it rose by 8.65%, to 25.75 Hong Kong dollars, with a turnover of 66.0064 million Hong Kong dollars.
Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space
Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.
HK stocks unusual movement|Genting New Star rises nearly 5%, with strong certainty in short-term innovative pipeline layout and long-term growth potential.
gelonkhui October 17th | Genting Xin Yao (1952.HK) rose nearly 5%, reaching a high of 23.95 Hong Kong dollars. Over the past two months, the stock price of Genting Xin Yao has cumulatively risen by more than 65%. On the news front, the previous announcement of a rate cut by the Federal Reserve to inject liquidity into the market, and the unexpected adjustment of domestic monetary policy in recent times have fully stimulated the vitality of the capital markets, with both the Hong Kong and A-share markets continuing to rise. Among them, the innovative drugs sector, due to its long-term valuation bottoming out and significant growth potential, has a higher investment value ratio, becoming one of the important directions worth paying attention to in this round of market trends. Genting Xin Yao, as a company focusing on innovative drugs and vaccines.
By looking through the sky, seize the investment opportunities behind the market frenzy with Xin Yao-B (1952.HK).
Recently, in addition to the Fed cutting interest rates to inject liquidity into the market, the unexpected adjustment of domestic monetary policy has fully stimulated the vitality of the capital markets.
Everest Medicines Grants Options, Awards Under Employees Incentive Schemes
No Data
No Data